BOSTON--(BUSINESS WIRE)-- EMD Serono, the healthcare business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, and President Donald J. Trump’s administration, today announced an agreement to ...

Merck's IVF drugs to be sold at 84% discount Merck to receive tariff protection in exchange for price cuts TrumpRX website to facilitate direct drug purchases by 2026 Merck to seek expedited US ...

After delivering solid sales growth in a difficult 2025, Germany’s Merck KGaA may have a tougher go of things this year, which the company is crediting in part to a predicted onslaught of U.S.

Merck KGaA forecast lackluster earnings in guidance that reflects generic competition for its multiple sclerosis blockbuster drug Mavenclad, but not the potential benefits from the US launch of a ...